Considering 95% of patients in our study were EGFR-overexpressed, and 10 responses all occurred in this patient population, EGFR overexpression could be used as a predicted biomarker in the future study of larotinib in ESCC. Here, EGFR is linked to esophageal squamous cell carcinoma.